Kurzfassung

In this study we aim to investigate the role of cancer stem cells (CSC) and immune modulators as putative factors for inducing tumour resistance against anti EGFR agents. The CSC markers LGR4, LGR5, CXCR4, CD133 and CD44 as well as the immune marker PD-L1 are overexpressed in gastic cancer and are associated with a worse prognosis. Furthermore, they have been shown in different studies to interact and crosslink with the EGFR- pathway promoting tumour formation and survival.
Testing the...In this study we aim to investigate the role of cancer stem cells (CSC) and immune modulators as putative factors for inducing tumour resistance against anti EGFR agents. The CSC markers LGR4, LGR5, CXCR4, CD133 and CD44 as well as the immune marker PD-L1 are overexpressed in gastic cancer and are associated with a worse prognosis. Furthermore, they have been shown in different studies to interact and crosslink with the EGFR- pathway promoting tumour formation and survival.
Testing the expression of CD44, CD133, CXCR4, LGR4, LGR5 and PD-L1 in tumour tissues of patients with metastatic gastric cancer under treatment with and without EGFR-antibodies might provide useful information concerning the putative predictive role of these biomarkers in choosing the right treatment in patients with advanced esophagogastric cancer
 
 » weiterlesen» einklappen